HUE066468T2 - Idegnyugtató norketamin vegyületek és eljárások - Google Patents
Idegnyugtató norketamin vegyületek és eljárásokInfo
- Publication number
- HUE066468T2 HUE066468T2 HUE15856205A HUE15856205A HUE066468T2 HU E066468 T2 HUE066468 T2 HU E066468T2 HU E15856205 A HUE15856205 A HU E15856205A HU E15856205 A HUE15856205 A HU E15856205A HU E066468 T2 HUE066468 T2 HU E066468T2
- Authority
- HU
- Hungary
- Prior art keywords
- neuro
- methods
- attenuating norketamine
- compounds
- norketamine compounds
- Prior art date
Links
- BEQZHFIKTBVCAU-UHFFFAOYSA-N 2-amino-2-(2-chlorophenyl)-1-cyclohexanone Chemical class C=1C=CC=C(Cl)C=1C1(N)CCCCC1=O BEQZHFIKTBVCAU-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/001—Acyclic or carbocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
- C07C225/20—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Inorganic Chemistry (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462074645P | 2014-11-04 | 2014-11-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
HUE066468T2 true HUE066468T2 (hu) | 2024-08-28 |
Family
ID=55909773
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE15856205A HUE066468T2 (hu) | 2014-11-04 | 2015-11-04 | Idegnyugtató norketamin vegyületek és eljárások |
Country Status (18)
Country | Link |
---|---|
US (5) | US10252982B2 (hu) |
EP (2) | EP3215147B1 (hu) |
JP (2) | JP6882180B2 (hu) |
KR (1) | KR102604397B1 (hu) |
CN (2) | CN115521217A (hu) |
AU (1) | AU2015343083B2 (hu) |
CA (1) | CA2966737A1 (hu) |
DK (1) | DK3215147T3 (hu) |
ES (1) | ES2977383T3 (hu) |
FI (1) | FI3215147T3 (hu) |
HU (1) | HUE066468T2 (hu) |
LT (1) | LT3215147T (hu) |
PL (1) | PL3215147T3 (hu) |
PT (1) | PT3215147T (hu) |
RS (1) | RS65411B1 (hu) |
RU (1) | RU2771275C2 (hu) |
SI (1) | SI3215147T1 (hu) |
WO (1) | WO2016073653A1 (hu) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015065547A1 (en) | 2013-10-31 | 2015-05-07 | Cima Labs Inc. | Immediate release abuse-deterrent granulated dosage forms |
CN115521217A (zh) | 2014-11-04 | 2022-12-27 | 阿莫萨治疗公司 | 神经衰减性氯胺酮和去甲氯胺酮化合物、其衍生物和方法 |
US11426366B2 (en) * | 2015-05-15 | 2022-08-30 | Arizona Board Of Regents On Behalf Of The Universsity Of Arizona | Compositions and methods for treating motor disorders |
CN107847469A (zh) | 2015-06-27 | 2018-03-27 | 美国神农制药责任有限公司 | 氯胺酮透皮递送系统 |
JP2019513707A (ja) * | 2016-04-11 | 2019-05-30 | クレキシオ バイオサイエンシーズ エルティーディー. | 重水素化ケタミン誘導体 |
US20190256487A1 (en) * | 2016-09-16 | 2019-08-22 | BioPharmaWorks, LLC | Hydroxynorketamine prodrugs |
CN110167541A (zh) * | 2016-10-27 | 2019-08-23 | 国立大学法人千叶大学 | (s)-去甲氯胺酮及其盐作为药物的应用 |
EP3609481A4 (en) | 2017-04-13 | 2021-05-26 | Ovid Therapeutics Inc. | DEVELOPMENTAL ENCEPHALOPATHY TREATMENT METHODS |
EP3641742A2 (en) * | 2017-06-23 | 2020-04-29 | Develco Pharma Schweiz AG | Hydroxynorketamine for the use in the treatment of depression |
JP2020529445A (ja) | 2017-07-31 | 2020-10-08 | スモール ファーマ リミテッド | ヒドロキシノルケタミンの結晶形態 |
US11471415B2 (en) | 2017-10-10 | 2022-10-18 | Douglas Pharmaceuticals, Ltd. | Extended release pharmaceutical formulation and methods of treatment |
CN111630026A (zh) * | 2017-10-10 | 2020-09-04 | 道格拉斯制药有限公司 | 缓释药物制剂和治疗方法 |
US12090123B2 (en) | 2017-10-10 | 2024-09-17 | Douglas Pharmaceuticals Ltd. | Extended release pharmaceutical formulation |
US10441544B2 (en) | 2017-10-10 | 2019-10-15 | Douglas Pharmaceuticals, Ltd. | Extended release pharmaceutical formulation |
WO2020194087A2 (en) * | 2019-03-25 | 2020-10-01 | Douglas Pharmaceuticals Ltd. | Extended release pharmaceutical formulation |
US10869838B2 (en) | 2017-10-10 | 2020-12-22 | Douglas Pharmaceuticals, Ltd. | Extended release pharmaceutical formulation |
EP3501503A1 (en) * | 2017-12-22 | 2019-06-26 | Cosmo Technologies Ltd. | Solid delivery composition |
WO2019160057A1 (ja) | 2018-02-15 | 2019-08-22 | 国立大学法人千葉大学 | 炎症性疾患若しくは骨疾患の予防又は治療剤及び医薬組成物 |
US11426367B2 (en) | 2018-05-04 | 2022-08-30 | Perception Neuroscience, Inc. | Methods of treating substance abuse |
WO2020003195A1 (en) | 2018-06-27 | 2020-01-02 | Clexio Biosciences Ltd. | Method of treating major depressive disorder |
JP2022504036A (ja) | 2018-10-05 | 2022-01-13 | クレキシオ バイオサイエンシーズ エルティーディー. | 大うつ病性障害を治療するためのエスケタミンの投与計画 |
US20220062200A1 (en) | 2019-05-07 | 2022-03-03 | Clexio Biosciences Ltd. | Abuse-deterrent dosage forms containing esketamine |
WO2020225773A1 (en) | 2019-05-07 | 2020-11-12 | Clexio Biosciences Ltd. | Abuse-deterrent dosage forms containing esketamine |
EP4041209A4 (en) | 2019-10-11 | 2024-01-24 | Pike Therapeutics, Inc. | TRANSDERMAL COMPOSITIONS CONTAINING CANNABIDIOL (CBD) FOR USE IN THE TREATMENT OF SEIZURE DISORDERS |
WO2021137147A1 (en) | 2019-12-30 | 2021-07-08 | Clexio Biosciences Ltd. | Dosage regime with esketamine for treating major depressive disorder |
WO2021137148A1 (en) * | 2019-12-30 | 2021-07-08 | Clexio Biosciences Ltd. | Dosage regime with esketamine for treating neuropsychiatric or neurological conditions |
AU2021275863A1 (en) | 2020-05-20 | 2023-02-02 | Certego Therapeutics Inc. | Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders |
CN114524737B (zh) * | 2020-11-23 | 2024-10-22 | 江苏恒瑞医药股份有限公司 | 一种取代的环己酮类化合物 |
GB202019952D0 (en) * | 2020-12-17 | 2021-02-03 | Neurocentrx Pharma Ltd | Novel compositions |
CA3217153A1 (en) * | 2021-04-30 | 2022-11-03 | Philip E. Wolfson | Ketamine and cannabis for the treatment of emotional disorders |
CN116730853A (zh) * | 2022-03-04 | 2023-09-12 | 上海致根医药科技有限公司 | 新型氨基酮类化合物及其制备方法和用途 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5250732A (en) | 1991-07-18 | 1993-10-05 | Genentech, Inc. | Ketamine analogues for treatment of thrombocytopenia |
AUPN605795A0 (en) | 1995-10-19 | 1995-11-09 | F.H. Faulding & Co. Limited | Analgesic pharmaceutical composition |
CA2506615A1 (en) | 2002-11-18 | 2004-06-03 | Yaupon Therapeutics, Inc. | Analgesic uses of norketamine and ketamine/norketamine prodrugs |
US20100076087A1 (en) * | 2005-10-06 | 2010-03-25 | Auspex Pharmaceuticals, Inc. | Methods of reduction of interpatient variability |
US8765178B2 (en) | 2006-07-19 | 2014-07-01 | Watson Laboratories, Inc. | Controlled release formulations and associated methods |
CN101765582A (zh) * | 2007-04-26 | 2010-06-30 | 奥斯拜客斯制药有限公司 | 氘标记的氯胺酮 |
WO2009131794A1 (en) | 2008-03-27 | 2009-10-29 | University Of Kentucky Research Foundation | Opioid-ketamine and norketamine codrug combinations for pain management |
US9913803B2 (en) | 2013-08-26 | 2018-03-13 | Amorsa Therapeutics, Inc. | Single-layer oral dose of neuro-attenuating ketamine |
CN115521217A (zh) | 2014-11-04 | 2022-12-27 | 阿莫萨治疗公司 | 神经衰减性氯胺酮和去甲氯胺酮化合物、其衍生物和方法 |
-
2015
- 2015-11-04 CN CN202211196697.5A patent/CN115521217A/zh active Pending
- 2015-11-04 US US15/524,224 patent/US10252982B2/en active Active
- 2015-11-04 LT LTEPPCT/US2015/059113T patent/LT3215147T/lt unknown
- 2015-11-04 CA CA2966737A patent/CA2966737A1/en active Pending
- 2015-11-04 SI SI201532004T patent/SI3215147T1/sl unknown
- 2015-11-04 WO PCT/US2015/059113 patent/WO2016073653A1/en active Application Filing
- 2015-11-04 HU HUE15856205A patent/HUE066468T2/hu unknown
- 2015-11-04 AU AU2015343083A patent/AU2015343083B2/en active Active
- 2015-11-04 RS RS20240383A patent/RS65411B1/sr unknown
- 2015-11-04 RU RU2017119222A patent/RU2771275C2/ru active
- 2015-11-04 EP EP15856205.8A patent/EP3215147B1/en active Active
- 2015-11-04 EP EP24159685.7A patent/EP4393487A3/en active Pending
- 2015-11-04 FI FIEP15856205.8T patent/FI3215147T3/fi active
- 2015-11-04 PT PT158562058T patent/PT3215147T/pt unknown
- 2015-11-04 CN CN201580072316.4A patent/CN107106529A/zh active Pending
- 2015-11-04 JP JP2017543308A patent/JP6882180B2/ja active Active
- 2015-11-04 KR KR1020177015310A patent/KR102604397B1/ko active Active
- 2015-11-04 ES ES15856205T patent/ES2977383T3/es active Active
- 2015-11-04 PL PL15856205.8T patent/PL3215147T3/pl unknown
- 2015-11-04 DK DK15856205.8T patent/DK3215147T3/da active
-
2019
- 2019-02-08 US US16/271,767 patent/US10981859B2/en active Active
-
2021
- 2021-03-09 US US17/196,986 patent/US11603348B2/en active Active
- 2021-05-06 JP JP2021078368A patent/JP2021120389A/ja active Pending
-
2022
- 2022-08-05 US US17/882,046 patent/US11613515B2/en active Active
-
2023
- 2023-02-14 US US18/168,950 patent/US20230192593A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201804070B (en) | Eif4-a-inhibiting compounds and methods related thereto | |
HUE066468T2 (hu) | Idegnyugtató norketamin vegyületek és eljárások | |
DK3237446T3 (en) | Anti-PD-1-antistoffer | |
IL252216A0 (en) | Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines | |
GB201413086D0 (en) | Methods | |
SG11201704473WA (en) | New methods and uses | |
GB201608779D0 (en) | Methods and compounds | |
HK1243342A1 (zh) | 化合物和方法 | |
GB201608776D0 (en) | Methods and compounds | |
GB201408745D0 (en) | Methods | |
HK1220676A1 (zh) | 配置件和方法 | |
GB201419650D0 (en) | Modified heterocyclase | |
GB201415250D0 (en) | Compound and method | |
GB201408091D0 (en) | Methods and uses | |
EP3185901C0 (en) | COMPOUND AND METHOD | |
GB201415685D0 (en) | Methods | |
AU5597P (en) | Lancalifornia Mandevilla sanderi | |
GB201404301D0 (en) | Compounds and combinations | |
GB201416086D0 (en) | Methods and uses | |
GB201416073D0 (en) | Methods and uses | |
GB201414122D0 (en) | Methods | |
GB201420773D0 (en) | Compound and method | |
GB201407596D0 (en) | New compounds and uses | |
GB201407599D0 (en) | New compounds and uses | |
GB201406991D0 (en) | Methods |